Jeremy M. Sternberg

Jeremy M. Sternberg

Auto-generated profile, based on publicly available information

Jeremy M. Sternberg

University of Aberdeen

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Infection and Immunity
Verified
Journal Article
Closed access
LMLorna MacLean
Lorna MacLean
JCJohn E. Chisi
John E. Chisi
MOMartin Odiit
Martin Odiit
WGWendy C. Gibson
Wendy C. Gibson
VFVanessa Ferris
Vanessa Ferris
JSJeremy M. Sternberg
Jeremy M. Sternberg
The mechanisms underlying virulence in human African trypanosomiasis are poorly understood, although studies with experimental mice suggest that unregulated host inflammatory responses are associated with disease severity. We identified two trypanosomiasis foci with dramatically different disease virulence profiles. In Uganda, infections followed an acute profile with rapid progression to the late stage (meningoencephalitic infection) in the majority of patients (86.8%). In contrast, infections in Malawi were of a chronic nature, in which few patients progressed to the late stage (7.1%), despite infections of several months' duration. All infections were confirmed to beTrypanosoma brucei rhodesienseby testing for the presence of the serum resistance-associated (SRA) gene, but trypanosomes isolated from patients in Uganda or Malawi were distinguished by anSRAgene polymorphism. The two disease profiles were associated with markedly different levels of tumor necrosis factor alpha (TNF-α) and transforming growth factor β (TGF-β) in plasma. In Uganda but not Malawi early-stage TNF-α was elevated, while in Malawi but not Uganda early-stage TGF-β was elevated. Thus, rapid disease progression in Uganda is associated with TNF-α-mediated inflammatory pathology, whereas in the milder disease observed in Malawi this may be ameliorated by counterinflammatory cytokines. These differing host responses may result either from differing virulence phenotypes of northern and southern trypanosomes or from immune response polymorphisms in the different host populations.

1 October 1992 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JSJeremy Sternberg
Jeremy Sternberg
FMFiona McGuigan
Fiona McGuigan

7 December 2010 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LMLorna M. MacLean
Lorna M. MacLean
MOMartin Odiit
Martin Odiit
JCJohn E. Chisi
John E. Chisi
PKPeter G. E. Kennedy
Peter G. E. Kennedy
JSJeremy M. Sternberg
Jeremy M. Sternberg
Diverse clinical features have been reported in human African trypanosomiasis (HAT) foci caused by Trypanosoma brucei rhodesiense (T.b.rhodesiense) giving rise to the hypothesis that HAT manifests as a chronic disease in South-East African countries and increased in virulence towards the North. Such variation in disease severity suggests there are differences in host susceptibility to trypanosome infection and/or genetic variation in trypanosome virulence. Our molecular tools allow us to study the role of host and parasite genotypes, but obtaining matched extensive clinical data from a large cohort of HAT patients has previously proved problematic. We present a retrospective cohort study providing detailed clinical profiles of 275 HAT patients recruited in two northern foci (Uganda) and one southern focus (Malawi) in East Africa. Characteristic clinical signs and symptoms of T.b.rhodesiense infection were recorded and the degree of neurological dysfunction determined on admission. Clinical observations were mapped by patient estimated post-infection time. We have identified common presenting symptoms in T.b.rhodesiense infection; however, marked differences in disease progression and severity were identified between foci. HAT was characterised as a chronic haemo-lymphatic stage infection in Malawi, and as an acute disease with marked neurological impairment in Uganda. Within Uganda, a more rapid progression to meningo-encephaltic stage of infection was observed in one focus (Soroti) where HAT was characterised by early onset neurodysfunction; however, severe neuropathology was more frequently observed in patients in a second focus (Tororo). We have established focus-specific HAT clinical phenotypes showing dramatic variations in disease severity and rate of stage progression both between northern and southern East African foci and between Ugandan foci. Understanding the contribution of host and parasite factors in causing such clinical diversity in T.b.rhodesiense HAT has much relevance for both improvement of disease management and the identification of new drug therapy. T. b. gambiense and T. b. rhodesiense cause human African trypanosomiasis (HAT). These parasite subspecies differ in their rate of progression to central nervous system (CNS) infection, and consequently to coma and death. Variation in disease progression and severity has also been documented between northern and southern East African T.b. rhodesiense HAT. However, it is unknown if this is caused by differences in patient susceptibility to infection, genetic variation in parasite virulence, or both, as despite the existence of good molecular tools, previous studies have involved limited numbers of HAT cases. In this paper we present extensive clinical data on T. b. rhodesiense cases and describe robust clinical profiles for three disease foci. Common presenting symptoms were identified. We also describe marked differences in disease progression and severity both between Ugandan and Malawi foci, and between two Ugandan foci (Tororo and Soroti) giving rise to three foci-specific clinical phenotypes ranging from a chronic haemo-lymphatic stage infection in Malawi, to rapid disease progression and neurological dysfunction in Soroti and severe neuropathology in Tororo cases. Most importantly, we have now established clinical focus-specific phenotypes that will be available to supplement host and parasite genetics studies to determine their contribution to HAT disease virulence.

1 October 2005 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
JSJeremy M. Sternberg
Jeremy M. Sternberg
JRJean Rodgers
Jean Rodgers
BBBarbara Bradley
Barbara Bradley
LMLorna MacLean
Lorna MacLean
MMMax Murray
Max Murray
PKPeter G.E. Kennedy
Peter G.E. Kennedy

1 November 2004 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
JSJ. M. Sternberg
J. M. Sternberg

25 October 2012 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LMLorna MacLean
Lorna MacLean
HRHansotto Reiber
Hansotto Reiber
PKPeter G. E. Kennedy
Peter G. E. Kennedy
JSJeremy M. Sternberg
Jeremy M. Sternberg
Human African trypanosomiasis progresses from an early (hemolymphatic) stage, through CNS invasion to the late (meningoencephalitic) stage. In experimental infections disease progression is associated with neuroinflammatory responses and neurological symptoms, but this concept requires evaluation in African trypanosomiasis patients, where correct diagnosis of the disease stage is of critical therapeutic importance. This was a retrospective study on a cohort of 115 T.b.rhodesiense HAT patients recruited in Eastern Uganda. Paired plasma and CSF samples allowed the measurement of peripheral and CNS immunoglobulin and of CSF cytokine synthesis. Cytokine and immunoglobulin expression were evaluated in relation to disease duration, stage progression and neurological symptoms. Neurological symptoms were not related to stage progression (with the exception of moderate coma). Increases in CNS immunoglobulin, IL-10 and TNF-α synthesis were associated with stage progression and were mirrored by a reduction in TGF-β levels in the CSF. There were no significant associations between CNS immunoglobulin and cytokine production and neurological signs of disease with the exception of moderate coma cases. Within the study group we identified diagnostically early stage cases with no CSF pleocytosis but intrathecal immunoglobulin synthesis and diagnostically late stage cases with marginal CSF pleocytosis and no detectable trypanosomes in the CSF. Our results demonstrate that there is not a direct linkage between stage progression, neurological signs of infection and neuroinflammatory responses in rhodesiense HAT. Neurological signs are observed in both early and late stages, and while intrathecal immunoglobulin synthesis is associated with neurological signs, these are also observed in cases lacking a CNS inflammatory response. While there is an increase in inflammatory cytokine production with stage progression, this is paralleled by increases in CSF IL-10. As stage diagnostics, the CSF immunoglobulins and cytokines studied do not have sufficient sensitivity to be of clinical value. Human African trypanosomiasis, caused by the parasites Trypanosoma brucei rhodesiense and T.b.gambiense, is clinically defined by two diagnostic stages, an early stage where the parasites appear to be localised to the blood and lymphatic systems, and a late stage where the parasites are also localised in the central nervous system (CNS) and cause a meningoencephalitis, which is fatal if untreated. We studied the progression between these stages of infection in T.b.rhodesiense infections in Uganda. Progression from early to late stage was associated with an increase in inflammatory responses in the CNS as measured by analysis of the cerebrospinal fluid. However, contrary to predictions based on experimental model studies, neither disease stage progression nor CNS inflammatory responses were directly associated with development of neurological symptoms. Our results suggest that biological basis of the boundary between the two diagnostic stages in this infection may not be clear cut, with implications for therapeutic decision making.